DOCSLIB.ORG

Antihypertensive Medications As Repurposed Treatments for Mood Disorders: Analysis of Linked Healthcare Data for 1.8 Million Patients

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antihypertensive Medications As Repurposed Treatments for Mood Disorders: Analysis of Linked Healthcare Data for 1.8 Million Patients medRxiv preprint doi: https://doi.org/10.1101/19001719; this version posted July 8, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Antihypertensive medications as repurposed treatments for mood disorders: analysis of linked healthcare data for 1.8 million patients. Authors: Richard J Shaw,1 Daniel Mackay,1 Jill P. Pell,1 Sandosh Padmanabhan,2 David S. Bailey,3 Daniel J. Smith1 1. Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK 2. Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK 3. Information Services Division, NHS National Services Scotland, Edinburgh, UK Financial support This project was supported by The Chief Scientist Office of Scotland award (D.J.S, D.M, J.P.P, S.P., grant number 173162-01) and the UK MRC Mental Health Data Pathfinder Award (D.J.S., J.P.P., grant number MC_PC_17217). Conflicts of interest None. Word Count: 3,876 Correspondence to: Dr. Richard Shaw Address: Institute of Health and Wellbeing, University of Glasgow, Public Health, 1 Lilybank Gardens, Glasgow, G12 8RZ, UK. Telephone : +44 (0) 141 330 2334. Email: [email protected]. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/19001719; this version posted July 8, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Background: Recent work suggests that antihypertensive medications may be useful as repurposed treatments for mood disorders. Using large-scale linked healthcare data we investigated whether certain classes of antihypertensive, such as angiotensin antagonists and calcium channel blockers, may have potential as repurposed treatments for Major Depressive Disorder (MDD) and bipolar disorder. Method: Two cohorts of patients treated with antihypertensives were identified from Scottish prescribing (2009-2016) and hospital admission (1981-2016) records. Eligibility for cohort membership was determined by receipt of a minimum of four prescriptions for antihypertensives within a 12-month window. One treatment cohort (n=538,730) included patients with no previous history of mood disorder, whereas the other (n=262,278) included those who did. Both cohorts were matched by age, sex and area deprivation to untreated comparators. Associations between antihypertensive treatment and new-onset MDD or bipolar episodes were investigated using Cox regression. Results: For patients without a history of mood disorder, antihypertensives were associated with increased risk of new-onset MDD. This was most marked for beta-blockers, with a hazard ratio (HR) of 2.68 (95%CI 2.45-2.92). For angiotensin antagonist monotherapy, the HR for new-onset MDD was 1.17 (95%CI 1.04-1.31). Some classes of antihypertensive were associated with protection against bipolar disorder, particularly angiotensin antagonists (HR 0.46; 95%CI 0.30-0.70). For patients with a past history of mood disorders, all classes of antihypertensives were associated with increased risk of future episodes of MDD. Conclusions: There was no evidence that antihypertensive medications prevented new episodes of MDD but angiotensin antagonists may represent a novel treatment avenue for bipolar disorder. 2 medRxiv preprint doi: https://doi.org/10.1101/19001719; this version posted July 8, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Introduction Major depressive disorder (MDD) and bipolar disorder (BD) are leading causes of disability globally (Ferrari et al., 2016, Vos et al., 2016). More than one third of MDD patients will not respond to first- line antidepressants (Linde et al., 2015) and BD is challenging to treat, with antidepressants ineffective for most patients (Sidor and Macqueen, 2011). In recent years there has been very little progress in the development of new medications for mood disorders but there is currently considerable interest in the possibility of repurposing medications from other areas of medicine. For example, it has been suggested that certain classes of antihypertensive medication (particularly calcium-channel blockers, CCBs and angiotensin antagonists, AA) may have a role as repurposed treatments for MDD or BD (Harrison et al., 2016, Harrison et al., 2019, Saavedra, 2017, Vian et al., 2017). To date, the evidence for repurposing antihypertensive drugs to treat MDD is limited (Chowdhury et al., 2019, Vian et al., 2017). AAs have been reported in small observational studies to be associated with better mental health outcomes (Ahola et al., 2014, Boal et al., 2016, Brownstein et al., 2018, Johansen et al., 2012, Nasr et al., 2011, Williams et al., 2016). However, a recent large linkage study found that although initial prescriptions for AAs were associated with increased risk of depression and bipolar disorder, people receiving longer-term prescriptions for AAs were not at increased risk (Kessing et al., 2019a, Kessing et al., 2019b). Since the 1980s, CCBs such as verapamil have been suggested as possible treatments for mania (Celano et al., 2011). This was not supported by a review of six double-blind randomised studies and 17 observational studies which found that no evidence for efficacy of CCBs in mania (Cipriani et al., 2016). Nonetheless, despite the relatively limited evidence base to date, CCBs remain candidates for repurposing in BD because of their biological plausibility (Cipriani et al., 2016). There is very little published work supporting the repurposing of other antihypertensive drug classes for MDD or BD. Case reports and some clinical trials have found that beta-blockers (BB) (particularly propranolol) may be associated with increased depressive features (Luijendijk and Koolman, 2012, Verbeek et al.) (although recent observational work suggests that BBs have little influence on mood disorder outcomes (Boal et al., 2016, Johansen et al., 2012, Ko et al., 2002, Luijendijk and Koolman, 2012, Nasr et al., 2011, Ranchord et al., 2016, Verbeek et al.)). It is possible that depressogenic effects are restricted to more lipophilic BB (such as propranolol) which cross the blood-brain barrier (Thiessen et al., 1990, Verbeek et al.). For other antihypertensive drugs, such as diuretics and centrally acting agents, almost no evidence of any influence on mood disorder outcomes has so far 3 medRxiv preprint doi: https://doi.org/10.1101/19001719; this version posted July 8, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. been described (Celano et al., 2011, Coyne et al., 2002, Hayes et al., 2019, Huffman and Stern, 2007, Nasr et al., 2011, Williams et al., 2016). Our primary goal was to use Scottish national-level routine healthcare data on over 1.8 million individuals (representing more than 6 million person-years of follow-up) to assess whether patients treated with specific classes of antihypertensive medication as monotherapy were less likely to experience new-onset mood disorder episodes. Methods Data Sources Within the National Services Scotland Safehaven, we created two datasets of cohorts and comparison groups by linking data from: the Community Health Index; Scottish Morbidity Records (SMR) datasets including SMR00 (Outpatient Attendance) from 1997 to 2016, SMR01 (General/Acute Inpatient and Day Case) from 1981 to 2016, and SMR04 (Mental Health Inpatient and Day Cases) from 1981 to 2016; the Prescribing Information System (PIS) from 2009 to 2016; and the National Records of Scotland death certificates from 1981 to 2016. Cohort 1 included patients treated with new-onset antihypertensive treatment who had no previous record of mood disorder. Cohort 2 included patients with new-onset antihypertensive treatment plus a past record of mood disorder. Ethical approval for the project was obtained from the Public Benefit and Privacy Panel at National Health Services Scotland Information and Statistics division. Time periods in which potential participants were eligible for inclusion were defined on the basis of prescriptions for antihypertensive medications, as well as prescriptions and hospital admission records for psychiatric disorders. To define the cohorts, we initially used PIS data from January 2009 to December 2016 to identify individuals who had a minimum of 4 prescriptions for antihypertensives (defined using British National Formulary (BNF)(Joint Formulary Committee, 2019) sections and paragraphs 2.2, 2.4, 2.5.5, and 2.6.2) within a window of up to 12 months, preceded by 6 months of no antihypertensive treatment record. Patients were then excluded from cohort 1 and included in cohort 2 if they had been prescribed psychiatric medication (indicated by BNF sections 4.1, 4.2, 4.3) within the same window. Following that, we also excluded people from cohort 1 and included them in cohort 2 if they had been admitted to hospital for psychiatric treatment (as indicated by a clinic appointment with the general psychiatry speciality in SMR00 database, ICD10 codes F10-F48, X60-X84 and Z91.5 and ICD9 codes 290-301 and 303-305 in the SMR01 database and a record in the SMR04 databases) during the antihypertensive treatment window and for the preceding 10 years. At this stage, the number of potential cohort 1 members was 968,930 for cohort 4 medRxiv preprint doi: https://doi.org/10.1101/19001719; this version posted July 8, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Load more

Recommended publications
  • Psychiatric Medications in Behavioral Healthcarev5
    Copyright © The University of South Florida, 2012 Psychiatric Medications in Behavioral Healthcare An Important Notice None of the pages in this tutorial are meant to be a replacement for professional help. The science of medicine is constantly changing, and these changes alter treatment and drug therapies as a result of what is learned through research and clinical experience. The author has relied on resources believed to be reliable at the time material was developed. However, there is always the possibility of human error or changes in medical science and neither the authors nor the University of South Florida can guarantee that all the information in this program is in every respect accurate or complete and they are not responsible for any errors or omissions or for the results obtained from the use of such information. Each person that reads this program is encouraged to confirm the information with other sources and understand that it not be interpreted as medical or professional advice. All medical information needs to be carefully reviewed with a health care provider. Course Objectives At the completion of this program participants should be able to: • Identify at 5 categories of medications used to treat the symptoms of psychiatric disorders, the therapeutic effects of medications in each category, and the side effects associated with medications in each category. • Identify at least 5 medications and the benefits of those medications as compared to the medications. • Identify at least 5 reasons that a person may stop taking medications or not take medications as prescribed. • Demonstrate your learned understanding of psychiatric medications by passing the combined post‐ tests.
    [Show full text]
  • The Psychoactive Effects of Psychiatric Medication: the Elephant in the Room
    Journal of Psychoactive Drugs, 45 (5), 409–415, 2013 Published with license by Taylor & Francis ISSN: 0279-1072 print / 2159-9777 online DOI: 10.1080/02791072.2013.845328 The Psychoactive Effects of Psychiatric Medication: The Elephant in the Room Joanna Moncrieff, M.B.B.S.a; David Cohenb & Sally Porterc Abstract —The psychoactive effects of psychiatric medications have been obscured by the presump- tion that these medications have disease-specific actions. Exploiting the parallels with the psychoactive effects and uses of recreational substances helps to highlight the psychoactive properties of psychi- atric medications and their impact on people with psychiatric problems. We discuss how psychoactive effects produced by different drugs prescribed in psychiatric practice might modify various disturb- ing and distressing symptoms, and we also consider the costs of these psychoactive effects on the mental well-being of the user. We examine the issue of dependence, and the need for support for peo- ple wishing to withdraw from psychiatric medication. We consider how the reality of psychoactive effects undermines the idea that psychiatric drugs work by targeting underlying disease processes, since psychoactive effects can themselves directly modify mental and behavioral symptoms and thus affect the results of placebo-controlled trials. These effects and their impact also raise questions about the validity and importance of modern diagnosis systems. Extensive research is needed to clarify the range of acute and longer-term mental, behavioral, and physical effects induced by psychiatric drugs, both during and after consumption and withdrawal, to enable users and prescribers to exploit their psychoactive effects judiciously in a safe and more informed manner.
    [Show full text]
  • Natural Psychoplastogens As Antidepressant Agents
    molecules Review Natural Psychoplastogens As Antidepressant Agents Jakub Benko 1,2,* and Stanislava Vranková 1 1 Center of Experimental Medicine, Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, 841 04 Bratislava, Slovakia; [email protected] 2 Faculty of Medicine, Comenius University, 813 72 Bratislava, Slovakia * Correspondence: [email protected]; Tel.: +421-948-437-895 Academic Editor: Olga Pecháˇnová Received: 31 December 2019; Accepted: 2 March 2020; Published: 5 March 2020 Abstract: Increasing prevalence and burden of major depressive disorder presents an unavoidable problem for psychiatry. Existing antidepressants exert their effect only after several weeks of continuous treatment. In addition, their serious side effects and ineffectiveness in one-third of patients call for urgent action. Recent advances have given rise to the concept of psychoplastogens. These compounds are capable of fast structural and functional rearrangement of neural networks by targeting mechanisms previously implicated in the development of depression. Furthermore, evidence shows that they exert a potent acute and long-term positive effects, reaching beyond the treatment of psychiatric diseases. Several of them are naturally occurring compounds, such as psilocybin, N,N-dimethyltryptamine, and 7,8-dihydroxyflavone. Their pharmacology and effects in animal and human studies were discussed in this article. Keywords: depression; antidepressants; psychoplastogens; psychedelics; flavonoids 1. Introduction 1.1. Depression Depression is the most common and debilitating mental disease. Its prevalence and burden have been steadily rising in the past decades. For example, in 1990, the World Health Organization (WHO) projected that depression would increase from 4th to 2nd most frequent cause of world-wide disability by 2020 [1].
    [Show full text]
  • Peri-Operative Medicine John Cohn
    Perioperative Medicine Steven L. Cohn (Editor) Perioperative Medicine Editor Steven L. Cohn Director – Medical Consultation Service Kings County Hospital Center Clinical Professor of Medicine SUNY Downstate Brooklyn, NY ISBN 978-0-85729-497-5 e-ISBN 978-0-85729-498-2 DOI 10.1007/978-0-85729-498-2 Springer London Dordrecht Heidelberg New York British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library Library of Congress Control Number: 2011931531 © Springer-Verlag London Limited 2011 Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permit- ted under the Copyright, Designs and Patents Act 1988, this publication may only be reproduced, stored or transmitted, in any form or by any means, with the prior permission in writing of the publishers, or in the case of reprographic reproduction in accordance with the terms of licenses issued by the Copyright Licensing Agency. Enquiries concerning reproduction outside those terms should be sent to the publishers. The use of registered names, trademarks, etc., in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore free for general use. Product liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature. Cover design: eStudioCalamar, Figueres/Berlin Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com) Preface Preoperative risk assessment and perioperative management are important aspects of clinical practice in internal medicine.
    [Show full text]
  • Mental Health Medications
    Mental Health Medications National Institute of Mental Health U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES UÊÊ >Ì>ÊÃÌÌÕÌiÃÊvÊi>Ì Contents Mental Health Medications ..............................................................1 What are psychiatric medications? .....................................................1 How are medications used to treat mental disorders? .......................................1 What medications are used to treat schizophrenia? ............................................2 What are the side effects? ............................................................2 How are antipsychotics taken and how do people respond to them? ...........................3 How do antipsychotics interact with other medications? ....................................3 What medications are used to treat depression? ..............................................4 What are the side effects? ............................................................4 How should antidepressants be taken? ..................................................5 Are herbal medicines used to treat depression? ...........................................5 FDA warning on antidepressants.......................................................6 What medications are used to treat bipolar disorder? . .7 Mood stabilizers ...................................................................7 Atypical antipsychotics ..............................................................7 Antidepressants ....................................................................7 What are the
    [Show full text]
  • Antipsychotics-2020.Pdf
    © Mind 2020 Antipsychotics Explains what antipsychotics are used for, how the medication works, possible side effects and information about withdrawal. If you require this information in Word document format for compatibility with screen readers, please email: [email protected] Contents What are antipsychotics? ...................................................................................................................... 2 Could antipsychotics help me? .............................................................................................................. 5 How to take antipsychotics safely ......................................................................................................... 9 What dosage of antipsychotics should I be on? .................................................................................. 15 Antipsychotics during pregnancy and breastfeeding ........................................................................... 17 What side effects can antipsychotics cause? ....................................................................................... 20 What is a depot injection? ................................................................................................................... 30 How can I compare different antipsychotics? ..................................................................................... 31 Can I come off antipsychotics? ............................................................................................................ 41 Alternatives to antipsychotics
    [Show full text]
  • 8Th International Congress on Psychopharmacology & 4Th International Symposium on Child and Adolescent Psychopharmacology
    Case Reports 8th International Congress on Psychopharmacology & 4th International Symposium on Child and Adolescent Psychopharmacology CASE REPORTS [Abstract:0003][Psychopharmacology] Quetiapine associated with angioedema Taha Can Tuman1, Bengu Altunay Tuman2, Betul Sereflican2, Osman Yildirim1 1Department of Psychiatry, Abant Izzet Baysal University, School of Medicine, Bolu, Turkey 2Department of Dermatology, Abant Izzet Baysal University, School of Medicine, Bolu, Turkey e-mail address: [email protected] Quetiapine is an atypical antipsychotic indicated for the treatment of schizophrenia and bipolar disorder, both manic and depressive episodes. Quetiapine is also widely off label used for treatment of various psychiatric disorders. Angioedema is characterized with swelling of deep dermis and subcutaneous tissues without itching, often seen around the eyes, lips and genitals where subcutaneous tissue is loose. Histamine and bradykinin release by stimulation of mast cells via foods, drugs, infections, and physical stimuli lead vascular permeability and dilatation. Drug-related angioedema is most commonly seen with ACE inhibitors and NSAIDs. Here, we report a male patient of angioedema associated with quetiapine use. Case: A 36 year-old male patient with a 12 years follow-up diagnosis of bipolar disorder presented to our outpatient clinic with symptoms of reduced sleep, hyperactivity, irritability, restlessness, excessive talkativeness, distractibility, flight of ideas, grandiose, and mystic delusions. His physical and laboratory examinations (complete blood count, renal and hepatic function tests, urinalysis, electrolytes, thyroid function tests, and sedimentation rate), electrocardiography, and magnetic resonance imaging were normal. The patient was diagnosed with bipolar disorder, manic episode with psychotic features according to the DSM-5. Quetiapine 100 mg/day was started in the first day of the hospitalization.
    [Show full text]
  • Downloaded 09/26/21 04:47 PM UTC Ona What, If Any, Extra-Pharmacological Factors Are Commonly SECTION 1 Related to the Adverse Reaction Known As a Bad Trip
    ORIGINAL ARTICLE Journal of Psychedelic Studies 2(1), pp. 53–60 (2018) DOI: 10.1556/2054.2018.001 First published online March 20, 2018 Inside bad trips: Exploring extra-pharmacological factors GENÍS ONA* Department of Anthropology, Rovira i Virgili University, Tarragona, Spain (Received: June 18, 2017; revised manuscript received: January 16, 2018; accepted: January 17, 2018) Objective: This study aimed to clarify the influence of extra-pharmacological factors in the etiology of bad trips,a common adverse reaction related to the consumption of psychedelic drugs. Methods: A descriptive approach was adopted. The information was collected using a web-based survey. The survey respondents volunteered to participate based on the condition that they had suffered a bad trip in the past. Results: This report reveals some variables that are commonly related to this adverse reaction (i.e., the recreational consumption of drugs, the consumption of drugs in large, open outdoor spaces, or being inexperienced with the drug). In addition, we note that some problems, which may be related to bad trips (i.e., mixing drugs, ignorance about the purity, or the dosage), can be solved through harm- reduction strategies. Conclusions: We found certain aspects that could be related to the appearance of a bad trip, but it is not possible to establish a causal connection. We recommend conducting prospective studies with larger samples to collect more information about the role of extra-pharmacological factors. Keywords: psychedelic, bad trip, drug, adverse reaction
    [Show full text]
  • Heat-Related Illness in Individuals Using Psychiatric Medication 2016
    Common psychotropic medications You can prevent that may impair the heat response heat-related illness! Trade Name Generic Name Abilify aripiprazole There are ways to stay cool when the Asendin amoxapine temperature is 85 degrees and above, especially Artane trihexyphenidyl with high humidity: Aventyl, Pamelor nortriptyline In general: Benadryl diphenhydramine • Try to stay in cool places. Brintellix vortioxetine • Eat regular light meals. Celexa citalopram Clozaril, Fazaclo, Versacloz clozapine • Drink plenty of fluids. Cogentin benztropine • Avoid coffee, tea and alcohol. Cymbalta duloxetine When indoors: Desyrel, Oleptro trazodone • Spend time in cooler rooms or air- Elavil amitriptyline conditioned areas. A shopping mall or Effexor venlafaxine library provides a cool place. Eskalith, Lithobid, Lithonate lithium Fanapt iloperidone • Keep windows shut and drapes closed Heat-related Fetzima levomilnacipran during the day. Geodon ziprasidone • Open windows in the evening when the air Haldol haloperidol outside is cooler. illness in Invega paliperidone • Avoid outdoor activity during the warmest Lexapro escitalopram parts of the day. Loxitane loxapine Latuda lurasidone • Take a cool shower or bath. individuals Navane thiothixene When outside: Norpramin desipramine • Apply sunscreen. Paxil paroxetine • Avoid prolonged exposure to direct sunlight. using psychiatric Phenergan promethazine • Wear loose-fitting and light-colored Pristiq desvenlafaxine clothing. Prolixin fluphenazine medication Prozac fluoxetine • Wear a hat and sunglasses. Rexulti brexpiprazole • Be aware of your environment (For Risperdal risperidone example, asphalt may be warmer than Saphris asenapine surrounding air temperature). 2016 Seroquel quetiapine Sinequan, Silenor doxepin Stelazine trifluoperazine Thorazine chlorpromazine Ohio Department of Mental Tofranil imipramine Health and Addiction Services Trilafon perphenazine 30 E. Broad St., 36th Floor Wellbutrin, Zyban bupropion Columbus, Ohio 43215 Viibryd vilazodone www.mha.ohio.gov Vrylar cariprazine 1-877-275-6364 Zoloft sertraline John R.
    [Show full text]
  • Module #5. Optional Training Psychotropic Medications And
    Module #5. Optional Training Psychotropic Medications and Children and Adolescents The following training provides information on psychotropic medications, their use with children and adolescents in general and with children and adolescents in foster care in particular, and specific types of psychotropic medications. There are eight sections in this training: Section #1: What are Psychotropic Medications? Section #2: Psychotropic Medication and Children and Adolescents Section #3: Psychotropic Medications and Children in Foster Care Section #4: Psychotropic Medications and Anxiety Disorders (Including PTSD) Section #5: Psychotropic Medication and ADHD Section #6: Depression and Psychotropic Medications Section #7: Psychotropic Medication and Bipolar Disorder Module #8: Psychotropic Medication and Schizophrenia Section #9: Resources on Psychotropic Medications Here are the learning objectives for this training. At the conclusion of this training, you will be able to: #1. State why psychotropic medications are generally used. #2. Name two critical issues that must be taken into account in using psychotropic medications with children and adolescents. #3. Identify four concerns about the current usage of psychotropic medications with children and adolescents in foster care. #4. Identify three major types of psychotropic medications used to treat anxiety disorders, including PTSD. #5. Name three very common side effects of psychotropic medications used for the treatment of ADHD. #6. Describe the FDA warning regarding the use of antidepressants in the treatment of children and adolescents 1 #7. Identify two major types of psychotropic medications used in the treatment of bipolar disorder #8. Define an “atypical antipsychotic” and list two benefits of this type of drug for the treatment of schizophrenia. At the conclusion of this training, there is a test that you can take to assess your learning.
    [Show full text]
  • Psychiatric Medication Management
    Psychiatric Medication Management The cause of mental illness is not yet fully understood, but it is thought that both your biology and your stress level can contribute to the development of mental illness symptoms. Medications and coping strategies can help reduce your biological predisposition (vulnerability) and treat your symptoms of mental illness. They can be powerful tools in your journey toward recovery. This educational handout is designed to support you in taking your medications effectively. How can medications help with my symptoms? • It is possible that mental illnesses are related to an imbalance of chemicals in the cells of the brain. Taking prescribed medications can work to correct the imbalance. • By taking your medications regularly, you can lower the intensity of many symptoms, and specifically improve your concentration, mood, and ability to achieve your goals. Making your medications a priority over time can decrease your symptoms, prevent relapses and hospital stays, and improve the quality of your life. • You can move toward recovery by being informed about your prescribed medications and taking them regularly. Talk to your nurse or health care provider if you need education about a specific medication. What should I ask my health care provider about my medication? • How will the medicine benefit me? • How long will it take for the medication to work? • What are the possible side effects and what can be done about them? • Will I need any blood test monitoring for these medications? • Are there any alternatives? 9C Adult Psychiatry -1- What are some myths about taking medications? • I feel better now, so I don’t need to take my medication.
    [Show full text]
  • Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
    Effective 6/11/2020. Contact [email protected] for previous versions. Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline Note: Active Table of Contents – Click to follow link INTRODUCTION........................................................................................................................... 3 SCOPE....................................................................................................................................... 3 DEFINITIONS .............................................................................................................................. 3 RECOMMENDATIONS ................................................................................................................... 4 METHODOLOGY .........................................................................................................................28 COLLATERAL TOOLS & RESOURCES..................................................................................................31 APPENDIX A: PERIOPERATIVE MEDICATION MANAGEMENT .................................................................32 APPENDIX B: TREATMENT ALGORITHM FOR THE TIMING OF ELECTIVE NONCARDIAC SURGERY IN PATIENTS WITH CORONARY STENTS .....................................................................................................................58 APPENDIX C: METHYLENE BLUE AND SEROTONIN SYNDROME ...............................................................59 APPENDIX D: AMINOLEVULINIC ACID AND PHOTOTOXICITY
    [Show full text]